All In MedTech

FDA Clearance Tracker · P230007

TriClip G4 System

Premarket approval (PMA) is the pathway for the highest-risk devices. FDA reviews clinical evidence of safety and effectiveness before approving.

Last checked: Nov 19, 2026Latest source record: Apr 1, 2024 (this decision)Source: openFDAMethods & limitations

PMAFirst of its product codeBreakthrough

Decided

Apr 1, 2024

Approved

Time to decision

396 days

Received Mar 2, 2023. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA

Device class

Class III

The decision

FDA number
P230007
Device name
TriClip G4 System
Applicant location
St. Paul, MN
Received
Mar 2, 2023
Decided
Apr 1, 2024
Decision
Approved
Supplements
22 in FDA's data for this PMA. See them on the FDA record

Device type

Device class
Class III

Every decision under product code NPS

FDA's approval statement

As written in FDA's record.

Approval for the TriClip G4 System. This device is indicated for improving quality of life and functional status in patients with symptomatic severe tricuspid regurgitation despite optimal medical therapy, who are at intermediate or greater risk for surgery and in whom transcatheter edge-to-edge valve repair is clinically appropriate and is expected to reduce tricuspid regurgitation severity to moderate or less, as determined by a multidisciplinary heart team.

How new is this?

These are facts about FDA's records. They are not a judgment about the device.

  • This is the earliest decision in FDA's data under product code NPS (Tricuspid valve repair device, percutaneously delivered).
  • It is on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026).

Source documents

Other decisions for ABBOTT MEDICAL

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

5 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.